|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
150,780,000 |
Market
Cap: |
59.38(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.3938 - $0.3938 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Nabriva Therapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company engaged in the research, development and commercialization of anti-infective agents to treat serious infections. Co. has approval from the U.S. Food and Drug Administration for XENLETA for the treatment of adults with community-acquired bacterial pneumonia. XENLETA is an oral and intravenous treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. Co.'s CONTEPO is a potentially epoxide antibiotic for intravenous use in the U.S. for complicated urinary tract infections. Co. may develop XENLETA and CONTEPO for additional indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
51,839 |
Total Sell Value |
$0 |
$0 |
$0 |
$9,588 |
Total People Sold |
0 |
0 |
0 |
6 |
Total Sell Transactions |
0 |
0 |
0 |
6 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-08-07 |
4 |
S |
$10.50 |
$186,795 |
D/D |
(17,790) |
2,373,387 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-07-28 |
4 |
S |
$10.51 |
$69,195 |
D/D |
(6,585) |
2,391,177 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-07-24 |
4 |
S |
$10.50 |
$1,680 |
D/D |
(160) |
2,397,762 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-07-20 |
4 |
S |
$10.50 |
$246,173 |
D/D |
(23,445) |
2,397,922 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-07-19 |
4 |
S |
$10.50 |
$218,253 |
D/D |
(20,786) |
2,421,367 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-07-03 |
4 |
S |
$10.95 |
$124,250 |
D/D |
(11,352) |
2,571,877 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-06-30 |
4 |
S |
$10.94 |
$19,420 |
D/D |
(1,775) |
2,583,229 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-06-29 |
4 |
S |
$10.72 |
$17,189 |
D/D |
(1,603) |
2,585,004 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-06-28 |
4 |
S |
$11.10 |
$53,158 |
D/D |
(4,789) |
2,586,697 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-06-27 |
4 |
S |
$10.83 |
$23,457 |
D/D |
(2,166) |
2,591,396 |
|
- |
|
Talbot George Harrison |
Director |
|
2017-06-19 |
4 |
S |
$91.00 |
$4,186 |
D/D |
(46) |
3,179 |
|
- |
|
Talbot George Harrison |
Director |
|
2017-06-16 |
4 |
S |
$93.50 |
$2,244 |
D/D |
(24) |
3,225 |
|
- |
|
Talbot George Harrison |
Director |
|
2017-06-15 |
4 |
S |
$94.10 |
$9,410 |
D/D |
(100) |
3,249 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-06-01 |
4 |
S |
$11.27 |
$4,508 |
D/D |
(400) |
2,593,562 |
|
- |
|
Talbot George Harrison |
Director |
|
2017-05-30 |
4 |
S |
$101.00 |
$21,265 |
D/D |
(210) |
3,349 |
|
- |
|
Talbot George Harrison |
Director |
|
2017-05-25 |
4 |
S |
$100.50 |
$29,693 |
D/D |
(295) |
3,559 |
|
- |
|
Talbot George Harrison |
Director |
|
2017-05-23 |
4 |
S |
$99.70 |
$2,991 |
D/D |
(30) |
3,854 |
|
- |
|
Talbot George Harrison |
Director |
|
2017-05-16 |
4 |
S |
$102.27 |
$15,413 |
D/D |
(150) |
3,884 |
|
- |
|
Talbot George Harrison |
Director |
|
2017-05-15 |
4 |
S |
$101.50 |
$5,075 |
D/D |
(50) |
4,034 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-04-28 |
4 |
S |
$11.03 |
$166,813 |
D/D |
(15,130) |
2,593,962 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-04-27 |
4 |
S |
$11.00 |
$1,100 |
D/D |
(100) |
2,609,092 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-04-26 |
4 |
S |
$11.00 |
$7,799 |
D/D |
(709) |
2,609,192 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-04-21 |
4 |
S |
$11.04 |
$28,937 |
D/D |
(2,622) |
2,609,901 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-04-20 |
4 |
S |
$11.00 |
$3,575 |
D/D |
(325) |
2,612,523 |
|
- |
|
Hbm Bioventures Cayman Ltd |
10% Owner |
|
2017-04-19 |
4 |
S |
$11.07 |
$130,434 |
D/D |
(11,785) |
2,612,848 |
|
- |
|
323 Records found
|
|
Page 12 of 13 |
|
|